Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody.
Few patients with Behçet's syndrome have gastrointestinal ulceration. Such patients are difficult to treat and have a higher mortality. Faced with refractory symptoms in two patients with intestinal Behçet's, we used the tumour necrosis factor alpha (TNF-alpha) monoclonal antibody inflixim...
Κύριοι συγγραφείς: | Travis, S, Czajkowski, M, McGovern, D, Watson, R, Bell, A |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2001
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
ανά: Elliot, M, κ.ά.
Έκδοση: (2008) -
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
ανά: Elliott, M, κ.ά.
Έκδοση: (1993) -
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
ανά: Elliott, M, κ.ά.
Έκδοση: (1994) -
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
ανά: Jihye Park, κ.ά.
Έκδοση: (2018-11-01) -
What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
ανά: Feldmann, M
Έκδοση: (1996)